Search

Aim. This study is an attempt to provide an analysis of the influence of implementation of cognitive behavioral intervention (CBI) in patients after cardiovascular implantable electronic device (CIED) implantation on the quality of life following the procedure as well as the level of illness acceptance. Method. The study group consisted of patients who underwent standard medical care related to CIED implantation and who additionally received CBI. Patients who received only standard medical care related to CIED implantation constituted a control group. CBI consisted of four sessions conducted over 30 (±3) days after the implantation. Demographic, clinical and psychological factors were assessed. The Acceptance of Illness Scale (AIS) and EuroQol-5D (EQ-5D) were applied. Results. In total, 128 patients (women: 36.7%, mean age 64.5 ± 8.9) were included in the study. The proposed cycle of four structured CBI meetings was well accepted by the patients, which is confirmed by their high turnout for these meetings. After six months, quality of life indices were significantly improved in cardiac electrotherapy recipients assigned to CBI, including: Visual Analogue Scale EQ-5D (80.2 ± 11.8 vs. 64.9 ± 14.3; p < 0.0001) and better acceptance of illness (AIS: 35.6 ± 4.3 vs. 28.7 ± 6.1; p < 0.0001). Conclusions. Implementation of CBI in patients after CIED implantation significantly improved indices of quality of life as well as illness acceptance, when compared to the control group of patients in standard care following electrotherapy. CBI showed multiple benefits in this population, as well as ensures the fulfilment of its expected therapeutic effect, while short duration of the intervention did not prolong the hospitalization itself. [ABSTRACT FROM AUTHOR]

Introduction. Sexual activity constitutes a significant aspect of health considerably influencing self-assessment of the quality of life. In Poland, data regarding the return in patients with ischaemic heart disease (IHD) to sexual activity are scarce and inadequate. Aim. The aim of this work is to analyse the return to sexual activity in patients with IHD after a hospitalisation related to invasive diagnostics of coronary arteries as well as to identify predisposing factors associated with cessation of sexual activity. Material and methods. 98 patients with angiographically documented IHD were involved in retrospective analysis. 46 patients (46.9%) were diagnosed with myocardial infarction (MI), 29 (29.6%) with stable angina (SA) and 23 (23.5%) with unstable angina (UA). Demographic, clinical and psychological factors were assessed. Beck Depression Inventory, State-Trait Anxiety Inventory, Acceptance of Illness Scale, and EuroQol-5D health questionnaires were used. Results. The cessation of sexual activity after a hospitalisation due to invasive diagnostics of coronary arteries was noted almost in 1/3 of the IHD patients within 6-months observation period. There were no statistically significant differences in the percentages of sexually active and inactive patients related to gender. The elderly patients were more likely to cease sexual activity (p = 0.006). Sexually active patients also represented significantly lower level of anxiety-trait (p = 0.0003) and anxiety-state (p = 0.001). They also had a higher level of the acceptance of the disease (p = 0.002) at the end of hospitalisation and presented significantly lower severity of depression (p = 0.02). Conclusions. Cessation of sexual activity in patients with IHD after a hospitalisation due to coronarography is associated with their older age, being single, obesity, lower quality of life, depression, higher level of anxiety, and lower acceptance of illness. Underestimating or omitting the realm of sexual health of hospitalised patients with IHD affects the patients’ return to sexual activity. Patients with IHD, who decided to discuss, during their hospitalisation, the impact of cardiac disease and the invasive procedure they had undergone on their sexual activity, more frequently return to sexual activity over the 6-months observation period. [ABSTRACT FROM AUTHOR]

Copyright of Polish Journal of Cardiology / Polski Przeglad Kardiologiczny is the property of Cornetis SP. Z.O.O. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Polish Journal of Cardiology / Polski Przeglad Kardiologiczny is the property of Cornetis SP. Z.O.O. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Polish Journal of Cardiology / Polski Przeglad Kardiologiczny is the property of Cornetis SP. Z.O.O. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Polish Journal of Cardiology / Polski Przeglad Kardiologiczny is the property of Cornetis SP. Z.O.O. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Polish Journal of Cardiology / Polski Przeglad Kardiologiczny is the property of Cornetis SP. Z.O.O. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Polish Journal of Urology / Urologia Polska is the property of Urologia Polska and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Polish Journal of Cardiology / Polski Przeglad Kardiologiczny is the property of Cornetis SP. Z.O.O. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Anticoagulants are the cornerstone of current acute coronary syndrome (ACS) therapy; however, anticoagulation regimens that aggressively reduce ischemic events are almost uniformly associated with more bleeding. REG1, an anticoagulation system, consists of RB006 (pegnivacogin), an RNA oligonucleotide factor IXa inhibitor, and RB007 (anivamersen), its complementary controlling agent. Phase I and IIa studies defined predictable relationships between doses of RB006, RB007, and degree of antifactor IX activity. The efficacy and safety of REG1 for the treatment of patients with ACS managed invasively and the safety of reversing RB006 with RB007 after cardiac catheterization are unknown. Randomized, partially-blinded, multicenter, active-controlled, dose-ranging study assessing the safety, efficacy, and pharmacodynamics of the REG1 anticoagulation system compared to unfractionated heparin or low molecular heparin in subjects with acute coronary syndrome (RADAR) is designed to assess both the efficacy of the anticoagulant RB006 and the safety of a range of levels of RB006 reversal with RB007. The objectives of RADAR are (1) to determine the safety of a range of levels of RB006 reversal with RB007 after catheterization, (2) to confirm whether a dose of 1 mg/kg RB006 results in near-complete inhibition of factor IXa in patients with ACS, and (3) to assess the efficacy of RB006 as an anticoagulant in patients with ACS undergoing percutaneous coronary intervention. [Copyright &y& Elsevier]